Bayer posted adjusted EBITDA of €4.45 billion, well above analysts' expectations of €3.93 billion, highlighting the growing importance of its agricultural segment in sustaining profitability.

At the center of this growth is the soybean seed business, which has gained momentum after resolving a licensing dispute with Corteva, improving market access and competitiveness. As a result, Bayer's Crop Science division saw earnings rise by 17.9% to €3.0 billion, reinforcing its role as the company's primary profit driver.

In a global context where demand for high-yield crop genetics and agricultural innovation continues to expand, soybeans have once again positioned themselves as a strategic asset-not only for farmers but also for multinational agribusiness companies seeking growth.

Bioinputs

Biologicals Are Not Replacing Agrochemicals: Here's How Leading Farmers Are Using Them

Litigation and pharma losses still weigh on strategy

Despite the strong agricultural performance, Bayer continues to face significant headwinds. The company is dealing with revenue losses from expiring patents on blockbuster drugs such as Xarelto and Eylea, impacting its pharmaceutical division.

Additionally, Bayer remains under pressure from thousands of lawsuits in the United States linked to its Roundup herbicide, with the U.S. Supreme Court now reviewing key aspects of the case. Legal uncertainty continues to weigh on investor sentiment and the company's valuation.

CEO Bill Anderson has been advancing a corporate restructuring strategy, although he recently paused a potential breakup of the conglomerate structure that had been under consideration.

At the same time, Bayer is strengthening its healthcare pipeline through the acquisition of Perfuse Therapeutics, in a deal worth up to $2.45 billion, aiming to reinforce its ophthalmology portfolio.